Emcure has made its foray in the field of bio-therapeutics through its wholly owned subsidiary Gennova Biopharmaceuticals Limited (GBL). Primary focus of research and development at GBL is in the areas of thrombolytics, nephrology and oncology and four major biologics (Tissue Plasminogen Activator- TNK-tPA, Granulocyte Macrophage Stimulating Factor-GM-CSF , Human Erythropoietin – rhEPO and Pegeylated GCSF) has been successfully developed and commercialized by GBL in the Indian market.